Closing the loop in genotype-matched oncology trial recruitment

A recent report from MD Anderson Cancer Center shows a troubling trend in the recruitment of genomic profiled cancer patients to clinical trials. The study, which explores the use of genomic testing to facilitate enrollment into patient-matched clinical trials, found that 789 of 2000 patients tested (39%) had at least one mutation making them eligible for a clinical trial designed to treat their specific tumor mutation. Yet only 11 percent of those patients went on to participate in these genotype-matched trials at MD Anderson.

In his recent blog, Brad Smith, PhD, Vice President, Advisory Services, QuintilesIMS, discusses some of the challenges to recruiting patients for these specialized trials and new, innovative patient- centric recruiting platforms addressing these challenges.

To read Brad's blog and understand more about these new recruiting platforms – please click here.

For further content relating to immuno-oncology trials - please click here.